← Back to search
BASILEA PHARMACEUTICA INTERNATIONAL LTD, ALLSCHWIL
Doing business as BASILEA PHARMACEUTICA INTERNATIONAL SA, ALLSCHWIL
ALLSCHWIL, 4123
Unclaimed
Prime contracting experience
4 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Prime | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | VENATORX PHARMACEUTICALS: NEW ANTIBIOTICS TO TREAT DRUG-RESISTANT GRAM-NEGATIVE BACTERIA INCLUDING PUBLIC HEALTH PATHOGENS. | — | $45,192,122 | Oct 7, 2026 | Sep 15, 2023 – Dec 31, 2027 |
| Prime | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | IGF::OT::IGF ADVANCED DEVELOPMENT OF CEFTOBIPROLE | — | $108,445,187 | Sep 23, 2026 | Apr 19, 2016 – Apr 18, 2026 |
| Prime | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESISTANT FUNGAL AND BACTERIAL INFECTIONS - OTA | — | $122,501,232 | Jul 28, 2026 | Sep 30, 2024 – Mar 31, 2032 |
| Prime | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | IGF::OT::IGF FOR OTHER FUNCTIONS THIS CONTRACT IS FOR THE CLINICAL DEVELOPMENT OF BAL30072, A NOVEL MONOSULFACTAM FOR THE TREATMENT OF INFECTIONS CAUSED BY MULTI-DRUG RESISTANT GRAM-NEGATIVE BACTERIAL PATHOGENS. | — | $13,096,576 | Oct 23, 2024 | Jun 19, 2013 – Sep 19, 2018 |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Subcontracting experience
3 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Subcontractor | Department of Health and Human Services | INFECTIONS CAUSED BY MULTIDRUG-RESISTANT BACTERIA HAVE BECOME ONE OF THE MOST IMPORTANT THREATS TO GLOBAL HEALTH, RESULTING IN AN ESTIMATED 1.27 MILLION GLOBAL DEATHS IN 2019. GRAM-NEGATIVE BACTERIA ARE OF PARTICULAR CONCERN, BECAUSE OF THEIR INTRINSIC RESISTANCE, RAPID ACQUISITION AND SPREAD OF NEW RESISTANCE, AND THE PAUCITY OF NOVEL ANTIBIOTIC DEVELOPMENT TARGETING THESE BACTERIA IN THE LAST DECADES. THE CENTERS FOR DISEASE CONTROL AND PREVENTION AND THE WORLD HEALTH ORGANIZATION IDENTIFIED CARBAPENEM-RESISTANT ENTEROBACTERIACEAE AS HIGH PRIORITY PATHOGENS FOR WHICH NEW AND EFFECTIVE ANTIBIOTIC TREATMENTS ARE URGENTLY NEEDED. BAL2420 (ALSO NAMED BAL0302420) IS A NOVEL ANTIBACTERIAL CANDIDATE FOR DEVELOPMENT AS INTRAVENOUS (IV) TREATMENT FOR SEVERE INFECTIONS CAUSED BY GRAM-NEGATIVE BACTERIA. THE COMPOUND IS A 16-MER CYCLIC PEPTIDE WITH A DISULFIDE BRIDGE AND AN INHIBITOR OF THE LIPOPOLYSACCHARIDE TRANSPORT PROTEIN A (LPTA), WHICH IS A NOVEL TARGET/MODE OF ACTION CURRENTLY NOT EXPLOITED BY ANY ANTIBIOTIC CURRENTLY AVAILABLE FOR CLINICAL USE. BAL2420 IS TO BE DEVELOPED AS A SAFE AND EFFECTIVE NOVEL TREATMENT OPTION FOR SERIOUS BACTERIAL INFECTIONS, INCLUDING BLOODSTREAM INFECTIONS ASSOCIATED WITH PNEUMONIA (HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA [HABP] / VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA [VABP]), COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAIS), AND COMPLICATED URINARY TRACT INFECTIONS (CUTIS), AND FOR CIAIS, CUTIS, AND HABP/VABP. IF SUCCESSFULLY DEVELOPED THE PROGRAM WILL PROVIDE A NOVEL CLASS OF ANTIBIOTICS TO TREAT LIFE-THREATENING INFECTIONS CAUSED BY DIFFICULT-TO-TREAT GRAM-NEGATIVE BACTERIA SUCH AS CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE) ADDRESSING A HIGH UNMET MEDICAL NEED. BAL2420 SHOWS POTENT, BACTERICIDAL ANTIMICROBIAL ACTIVITY AGAINST ENTEROBACTERIACEAE. ENTEROBACTERIACEAE ARE A FAMILY OF IMPORTANT PATHOGENS CAUSING INFECTIONS IN HUMANS AND INCLUDE BACTERIA SUCH AS ESCHERICHIA COLI OR KLEBSIELLA PNEUMONIAE. BAL2420 IS ALSO ACTIVE AGAINST ANTIBIOTIC-RESISTANT BACTERIA INCLUDING CARBAPENEM-RESISTANT ENTEROBACTERIACEAE, STRAINS RESISTANT TO COLISTIN, AN ANTIBIOTIC REGARDED AS LAST-RESORT THERAPY, AND AGAINST STRAINS WITH MBLS AND PBP3 MUTATIONS. BAL2420 HAS BEEN SHOWN TO BE EFFICACIOUS IN A WIDE VARIETY OF ANIMAL MODELS OF BACTERIAL INFECTION, INCLUDING LUNG AND URINARY TRACT MODELS. MOREOVER, THE CANDIDATE MOLECULE SHOWS FAVORABLE IN VITRO DMPK PROPERTIES, WITH GOOD PLASMA, LIVER MICROSOMAL, AND HEPATOCYTE STABILITIES, MODERATE PLASMA PROTEIN BINDING AND LOW POTENTIAL FOR DRUG-DRUG-INTERACTIONS. BAL2420 IS NOT GENOTOXIC OR PHOTOTOXIC AND HAS FAVORABLE SAFETY PROPERTIES WITH THE KIDNEY BEING THE PRIMARY TARGET ORGAN IN SYSTEMIC TOXICITY STUDIES. THE PROGRAM HAS NOW REACHED CLINICAL STAGE WITH THE CLINICAL TRIALS INFORMATION SYSTEM (CTIS) SUBMISSION ACHIEVED IN DECEMBER 2025. THE FIRST-IN-HUMAN STUDY (BAL2420-CP-101) INCLUDES SINGLE ASCENDING DOSE (SAD) AND MULTIPLE ASCENDING DOSE (MAD) PARTS AND BASILEA PLAN TO INITIATE THE FIRST IN-HUMAN CLINICAL STUDY IN THE FIRST HALF OF 2026. KC3788 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending | — | $9,053,709 | Apr 4, 2024 | — – — |
| Subcontractor | Department of Health and Human Services | INFECTIONS CAUSED BY MULTIDRUG-RESISTANT BACTERIA HAVE BECOME ONE OF THE MOST IMPORTANT THREATS TO GLOBAL HEALTH TODAY, RESULTING IN AN ESTIMATED 700,000 DEATHS ANNUALLY. GRAM-NEGATIVE BACTERIA ARE OF PARTICULAR CONCERN, BECAUSE OF THEIR INTRINSIC RESISTANCE, RAPID ACQUISITION AND SPREAD OF NEW RESISTANCE, AND THE PAUCITY OF NOVEL ANTIBIOTIC DEVELOPMENT TARGETING THESE BACTERIA IN THE LAST DECADE.
THE CENTERS FOR DISEASE CONTROL AND PREVENTION AND THE WORLD HEALTH ORGANIZATION IDENTIFIED CARBAPENEM-RESISTANT ENTEROBACTERIACEAE, CARBAPENEM-RESISTANT ACINETOBACTER BAUMANNII AND MULTIDRUG-RESISTANT (MDR) PSEUDOMONAS AERUGINOSA AS HIGH PRIORITY PATHOGENS FOR WHICH NEW AND EFFECTIVE ANTIBIOTIC TREATMENTS ARE URGENTLY NEEDED. THE CDC CLASSIFIES THE FIRST TWO GROUPS AS URGENT THREATS THAT ARE IMMINENT AND REQUIRE URGENT AND AGGRESSIVE ACTION, AND MDR P. AERUGINOSA INFECTIONS AS A SERIOUS THREAT THAT REQUIRES PROMPT AND SUSTAINED ACTION.
THE PROGRAM AIMS TO DISCOVER AND DEVELOP POTENT, SELECTIVE INHIBITORS OF 1-DEOXY-D-XYLULOSE 5-PHOSPHATE REDUCTOISOMERASE (DXR) FOR THE TREATMENT OF INFECTIONS CAUSED BY DRUG-RESISTANT GRAM-NEGATIVE BACTERIA. DXR CATALYZES THE FIRST COMMITTED STEP IN THE D-ERYTHRITOL 4-PHOSPHATE PATHWAY FOR ISOPRENOID SYNTHESIS, WHICH IS ESSENTIAL FOR GRAM-NEGATIVE BACTERIA. DXR IS NOT TARGETED BY CURRENTLY AVAILABLE ANTIBIOTICS AND, SINCE MAMMALS UTILIZE A DIFFERENT PATHWAY FOR ISOPRENOID SYNTHESIS, IT IS A VERY ATTRACTIVE TARGET FOR NOVEL ANTIBIOTICS. THE DXR ENZYME IS ESSENTIAL FOR SURVIVAL OF MANY BACTERIAL PATHOGENS INCLUDING THOSE IDENTIFIED BY THE CDC AND WHO AS HIGH PRIORITY PATHOGENS CAUSATIVE OF THE MOST THREATENING INFECTIONS.
THE PROGRAM IS CURRENTLY AT HIT-TO-LEAD RESEARCH STAGE. HITS HAVE BEEN IDENTIFIED THAT POTENTLY INHIBIT THE DXR ENZYME AND SHOW ANTIBACTERIAL ACTIVITY AGAINST SELECTED BACTERIA. THE ONGOING MEDICINAL CHEMISTRY PROGRAM FOCUSSES ON IMPROVING ENZYME INHIBITION, ANTIBACTERIAL ACTIVITY AND PHARMACOLOGICAL PROPERTIES OF THE CURRENT HIT COMPOUNDS AS WELL AS ENSURING LOW RESISTANCE DEVELOPMENT . TO THIS END, WE ARE SYSTEMATICALLY DETERMINING KEY PARAMETERS TO BUILD THE STRUCTURE-ACTIVITY-RELATIONSHIP SUPPORTING FURTHER IMPROVEMENT OF THE CURRENT HIT COMPOUNDS. WE ALSO MAKE USE OF RECENTLY OBTAINED INSIGHTS FROM X-RAY CRYSTALLOGRAPHY OF COMPLEXES BETWEEN THE TARGET ENZYME AND HIT COMPOUNDS. THE GOAL OF THIS PROGRAM IS THE IDENTIFICATION OF LEADS WITH POTENT BROAD-SPECTRUM ANTIBACTERIAL ACTIVITY, INCLUDING AGAINST HIGH-PRIORITY PATHOGENS, LOW RESISTANCE DEVELOPMENT POTENTIAL AND APPROPRIATE PHARMACOLOGICAL PROPERTIES.
THESE LEADS CAN THEN BE FURTHER OPTIMIZED TOWARDS A CLINICAL CANDIDATE READY TO START IND-ENABLING STUDIES.
THE ULTIMATE GOAL IS TO DEVELOP A SAFE AND EFFECTIVE NOVEL TREATMENT OPTION FOR SERIOUS INFECTIONS INCLUDING NOSOCOMIAL RESPIRATORY TRACT INFECTIONS. HOSPITAL-ACQUIRED PNEUMONIA IS THE LEADING CAUSE OF DEATH FROM NOSOCOMIAL INFECTIONS IN CRITICALLY ILL PATIENTS, WITH AN ESTIMATED ALL-CAUSE MORTALITY OF 20-30% OR EVEN 20-50% IN CASES OF VENTILATOR-ASSOCIATED PNEUMONIA. GRAM-NEGATIVE BACTERIA SUCH AS MEMBERS OF THE ENTEROBACTERIACEAE AND GRAM-NEGATIVE NON-FERMENTERS (E.G. P. AERUGINOSA AND A. BAUMANNII) ARE RESPONSIBLE FOR MOST CASES OF BACTERIAL HOSPITAL- AND VENTILATOR-ASSOCIATED PNEUMONIA. OTHER SERIOUS BACTERIAL INFECTIONS SUCH AS COMPLICATED INTRA-ABDOMINAL INFECTIONS AND COMPLICATED URINARY TRACT INFECTIONS INCLUDING PYELONEPHRITIS, ALSO PREDOMINANTLY CAUSED BY GRAM-NEGATIVE PATHOGENS, MAY REPRESENT FURTHER TARGET INDICATIONS OF THIS PROGRAM. 4500004475 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending | — | $79,408 | Mar 30, 2023 | — – — |
| Subcontractor | Department of Health and Human Services | INFECTIONS CAUSED BY MULTIDRUG-RESISTANT BACTERIA HAVE BECOME ONE OF THE MOST IMPORTANT THREATS TO GLOBAL HEALTH TODAY, RESULTING IN AN ESTIMATED 700,000 DEATHS ANNUALLY. GRAM-NEGATIVE BACTERIA ARE OF PARTICULAR CONCERN, BECAUSE OF THEIR INTRINSIC RESISTANCE, RAPID ACQUISITION AND SPREAD OF NEW RESISTANCE, AND THE PAUCITY OF NOVEL ANTIBIOTIC DEVELOPMENT TARGETING THESE BACTERIA IN THE LAST DECADE. THE CENTERS FOR DISEASE CONTROL AND PREVENTION AND THE WORLD HEALTH ORGANIZATION IDENTIFIED CARBAPENEM-RESISTANT ENTEROBACTERIACEAE, CARBAPENEM-RESISTANT ACINETOBACTER BAUMANNII AND MULTIDRUG-RESISTANT (MDR) PSEUDOMONAS AERUGINOSA AS HIGH PRIORITY PATHOGENS FOR WHICH NEW AND EFFECTIVE ANTIBIOTIC TREATMENTS ARE URGENTLY NEEDED. THE CDC CLASSIFIES THE FIRST TWO GROUPS AS URGENT THREATS THAT ARE IMMINENT AND REQUIRE URGENT AND AGGRESSIVE ACTION, AND MDR P. AERUGINOSA INFECTIONS AS A SERIOUS THREAT THAT REQUIRES PROMPT AND SUSTAINED ACTION. THE PROGRAM AIMS TO DISCOVER AND DEVELOP POTENT, SELECTIVE INHIBITORS OF 1-DEOXY-D-XYLULOSE 5-PHOSPHATE REDUCTOISOMERASE (DXR) FOR THE TREATMENT OF INFECTIONS CAUSED BY DRUG-RESISTANT GRAM-NEGATIVE BACTERIA. DXR CATALYZES THE FIRST COMMITTED STEP IN THE D-ERYTHRITOL 4-PHOSPHATE PATHWAY FOR ISOPRENOID SYNTHESIS, WHICH IS ESSENTIAL FOR GRAM-NEGATIVE BACTERIA. DXR IS NOT TARGETED BY CURRENTLY AVAILABLE ANTIBIOTICS AND, SINCE MAMMALS UTILIZE A DIFFERENT PATHWAY FOR ISOPRENOID SYNTHESIS, IT IS A VERY ATTRACTIVE TARGET FOR NOVEL ANTIBIOTICS. THE DXR ENZYME IS ESSENTIAL FOR SURVIVAL OF MANY BACTERIAL PATHOGENS INCLUDING THOSE IDENTIFIED BY THE CDC AND WHO AS HIGH PRIORITY PATHOGENS CAUSATIVE OF THE MOST THREATENING INFECTIONS. THE PROGRAM IS CURRENTLY AT HIT-TO-LEAD RESEARCH STAGE. HITS HAVE BEEN IDENTIFIED THAT POTENTLY INHIBIT THE DXR ENZYME AND SHOW ANTIBACTERIAL ACTIVITY AGAINST SELECTED BACTERIA. THE ONGOING MEDICINAL CHEMISTRY PROGRAM FOCUSSES ON IMPROVING ENZYME INHIBITION, ANTIBACTERIAL ACTIVITY AND PHARMACOLOGICAL PROPERTIES OF THE CURRENT HIT COMPOUNDS AS WELL AS ENSURING LOW RESISTANCE DEVELOPMENT . TO THIS END, WE ARE SYSTEMATICALLY DETERMINING KEY PARAMETERS TO BUILD THE STRUCTURE-ACTIVITY-RELATIONSHIP SUPPORTING FURTHER IMPROVEMENT OF THE CURRENT HIT COMPOUNDS. WE ALSO MAKE USE OF RECENTLY OBTAINED INSIGHTS FROM X-RAY CRYSTALLOGRAPHY OF COMPLEXES BETWEEN THE TARGET ENZYME AND HIT COMPOUNDS. THE GOAL OF THIS PROGRAM IS THE IDENTIFICATION OF LEADS WITH POTENT BROAD-SPECTRUM ANTIBACTERIAL ACTIVITY, INCLUDING AGAINST HIGH-PRIORITY PATHOGENS, LOW RESISTANCE DEVELOPMENT POTENTIAL AND APPROPRIATE PHARMACOLOGICAL PROPERTIES. THESE LEADS CAN THEN BE FURTHER OPTIMIZED TOWARDS A CLINICAL CANDIDATE READY TO START IND-ENABLING STUDIES. THE ULTIMATE GOAL IS TO DEVELOP A SAFE AND EFFECTIVE NOVEL TREATMENT OPTION FOR SERIOUS INFECTIONS INCLUDING NOSOCOMIAL RESPIRATORY TRACT INFECTIONS. HOSPITAL-ACQUIRED PNEUMONIA IS THE LEADING CAUSE OF DEATH FROM NOSOCOMIAL INFECTIONS IN CRITICALLY ILL PATIENTS, WITH AN ESTIMATED ALL-CAUSE MORTALITY OF 20-30% OR EVEN 20-50% IN CASES OF VENTILATOR-ASSOCIATED PNEUMONIA. GRAM-NEGATIVE BACTERIA SUCH AS MEMBERS OF THE ENTEROBACTERIACEAE AND GRAM-NEGATIVE NON-FERMENTERS (E.G. P. AERUGINOSA AND A. BAUMANNII) ARE RESPONSIBLE FOR MOST CASES OF BACTERIAL HOSPITAL- AND VENTILATOR-ASSOCIATED PNEUMONIA. OTHER SERIOUS BACTERIAL INFECTIONS SUCH AS COMPLICATED INTRA-ABDOMINAL INFECTIONS AND COMPLICATED URINARY TRACT INFECTIONS INCLUDING PYELONEPHRITIS, ALSO PREDOMINANTLY CAUSED BY GRAM-NEGATIVE PATHOGENS, MAY REPRESENT FURTHER TARGET INDICATIONS OF THIS PROGRAM. 4500004475 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending | — | $34,963 | Dec 1, 2022 | — – — |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Agencies supported
- Department of Health and Human ServicesGov-sourced